

Assessment of cognitive impairment in patients with vascular risk factors at 108 Military Central Hospital

Nguyen Hong Quan¹, Nguyen Tuong Ngoc Linh¹,
Le Dinh Uy¹, Le Thi Dieu Hong¹, Doan Thanh Cong¹,
Vu Quynh Huong¹, Nguyen Cao Vinh¹,
Tran Thi Ngoc Truong² and Dong Thi Thu Trang^{1*}

¹108 Military Central Hospital,
²103 Military Hospital

Summary

Objective: This study aimed to screen for cognitive impairment using the Mini-Mental State Examination (MMSE) scale in patients with vascular risk factors, such as hypertension, diabetes mellitus, dyslipidemia, and obesity. **Subject and method:** A total of 263 outpatients diagnosed with hypertension, diabetes, dyslipidemia, obesity, and/or a history of smoking were screened using the MMSE scale at 108 Military Central Hospital between March 2023 and October 2023. The study design was a prospective cross-sectional approach, with data analyzed using SPSS software. **Result:** Cognitive impairment was observed in 48% of the patients, predominantly in individuals over 60 years old. The prevalence of cognitive impairment increased with age and was significantly associated with vascular risk factors, including hypertension, diabetes, and dyslipidemia ($p < 0.05$). Patients with a higher number of risk factors demonstrated increased cognitive impairment ($p < 0.05$). **Conclusion:** There is a significant relationship between cognitive impairment, as assessed by the MMSE scale, and the presence of vascular risk factors. This study highlights the importance of early screening and intervention for cognitive decline in patients with comorbid vascular conditions.

Keywords: Cognitive impairment, Mini-Mental State Examination, vascular risk factors, hypertension, diabetes mellitus, dyslipidemia, obesity, aging population, dementia, cognitive decline.

I. BACKGROUND

Dementia represents a significant clinical syndrome, marked by memory loss and additional cognitive dysfunctions that disrupt daily social and occupational activities¹. As the global population ages, Vietnam faces rising dementia rates. Current estimates show that 4.5% to 10% of older adults in both Vietnam and worldwide experience dementia, with prevalence increasing with age²⁻⁴.

The number of elderly individuals with dementia is projected to surge from 25 million in

2000 to 63 million by 2030 and 114 million by 2050. This condition not only affects patients but also places immense burdens on caregivers, families, and healthcare systems, leading to an estimated \$818 billion in healthcare costs in 2015, equating to 1.09% of global GDP. Projections indicate these costs could reach \$2 trillion by 2030⁵.

In Vietnam, healthcare professionals extensively employ neuropsychological assessments to evaluate cognitive functions. Early screening for dementia is vital, enabling timely interventions that enhance outcomes for patients and communities. This study focuses on assessing cognitive impairment using the Mini-Mental State Examination (MMSE) among patients with vascular risk factors - such as

Received: 11 October 2024, Accepted: 20 November 2024

**Corresponding author: trangneuro@gmail.com -
108 Military Central Hospital*

hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking - who seek treatment at 108 Military Central Hospital.

II. SUBJECT AND METHOD

2.1. Subject

This study included 263 patients diagnosed with vascular risk factors hypertension, diabetes mellitus, dyslipidemia, obesity, and/or smoking. Participants received outpatient care at 108 Military Central Hospital and underwent cognitive screening using the Mini-Mental State Examination (MMSE) from March to October 2023.

2.2. Method

Study design: We conducted a prospective, cross-sectional study, with data analyzed using SPSS software, complemented by nationally validated statistical methods to enhance precision and analytical rigor.

Research procedure: Clinical assessments were performed by neurologists, incorporating neuropsychological tests and laboratory investigations. We also collected data from caregivers to ensure completeness. A standardized case report form captured all relevant parameters.

Clinical assessment: Neurologists conducted detailed evaluations based on the standardized form, confirming diagnoses of hypertension, diabetes mellitus, dyslipidemia, obesity, and/or smoking.

Neuropsychological testing: The MMSE consists of 11 questions assessing seven cognitive domains: Spatial orientation, temporal orientation, memory, attention, calculation, language, and visual construction. The assessment takes approximately 7 to 10 minutes.

Ethical considerations: Participation was voluntary, and subjects could withdraw at any time. Personal information was anonymized, securely stored, and used exclusively for research purposes.

III. RESULT

3.1. Characteristics of the study

Table 1. Distribution of age and gender in the study

Age Group	Male (n)	Female (n)	Total (n, %)
<60 years	72	28	28.5
60-79 years	52.4	47.6	68.8
>80 years	85.7	14.3	2.7
Total	58.9	41.1	100

Among the 263 patients participating in the study, 155 were male (58.9%) and 108 were female (41.1%). The age group of 60 to 80 years accounted for the highest proportion at 68.8%.

Table 2. Relationship between education level and cognitive impairment (MMSE scores)

Education level	With cognitive impairment (n, %)	No cognitive impairment (n, %)
Secondary school	25	7
High school	18	9
Vocational/College	57	53
University	19	50
Postgraduate	7	18
Total	126	137

The majority of elderly participants (61.3%) had an education level of secondary school or higher.

Table 3. Cognitive impairment by age group (MMSE scores)

Age group	With cognitive impairment			No impairment
	Mild impairment (MMSE 18-25)	Moderate impairment (MMSE 10-17)	Severe impairment (MMSE < 10)	
< 60 years	18	0	0	57
60-80 years	85	16	1	79

Age group	With cognitive impairment			No impairment
Level	Mild impairment (MMSE 18-25)	Moderate impairment (MMSE 10-17)	Severe impairment (MMSE < 10)	
> 80 years	5	1	0	1
Total (n)	108	17	1	137
Total (%)	41.1	6.5	0.3	52.1

Cognitive impairment was observed in 48% of patients, with mild impairment being the most prevalent at 41.1%.

Table 4. Relationship between vascular risk factors and cognitive Impairment

Cognitive Impairment	Risk factor			
	Smoking	Hypertension	Diabetes	Dyslipidemia
	n (%)	n (%)	n (%)	n (%)
No cognitive impairment	12 (41.4)	78 (45.1)	43 (42.6)	101 (57.7)
With cognitive impairment	17 (58.6)	95 (54.9)	58 (57.4)	74 (42.3)
Total	29 (100)	173 (100)	101 (100)	(100)
p	>0.05	<0.05	<0.05	<0.05

The results indicated a statistically significant increase in cognitive impairment among patients with vascular risk factors. However, smoking did not show statistical significance, likely due to an insufficient sample size.

Table 5. Association between risk factors and cognitive impairment

Cognitive impairment	Number of patients with risk factors			
	1	2	3	4
	n (%)	n (%)	n (%)	n (%)
No cognitive impairment	58 (58.6)	54 (48.6)	21 (42.0)	1 (33.3)
With cognitive impairment	41 (41.4)	57 (51.4)	29 (58.0)	2 (66.7)
Total	99 (100)	111 (100)	50 (100)	3 (100)
p	>0.05			

The results show that as the number of risk factors increases, cognitive impairment becomes more severe. However, this difference did not reach statistical significance, likely due to the small sample size.

IV. DISCUSSION

In our study, the majority of patients were aged between 60 and 80, with a male-to-female ratio of

58.9% to 41.1%. Cognitive impairment was observed in 48% of patients, with mild impairment being the most common (41.1%) based on MMSE scores. Cognitive decline increased significantly with age ($p<0.05$). These findings align with both domestic and international studies. For example, research on vascular dementia patients at Thanh Nhan Hospital showed a mean onset age of 67.8 years, with a

higher prevalence in men, potentially due to the higher number of vascular risk factors in males⁶.

Epidemiological studies show that the highest prevalence of dementia occurs in individuals aged 70 years and older, particularly in the United States, where the rate of dementia increases rapidly after age 65⁷. A study in northern Sweden found that 37.2% of individuals aged 60 and above suffered from dementia, significantly higher than the 2% prevalence in individuals younger than 60⁸. In our study, conducted in a population with multiple risk factors, the rate of dementia was as high as 48%. This increase in dementia prevalence with age can be attributed to the accumulation of pathological brain damage over time.

Hypertension has been identified as a critical factor in cognitive decline among the elderly. Our findings revealed a higher prevalence of dementia in hypertensive patients. Studies by Galstein FC et al. demonstrated that prolonged hypertension impairs cognitive functions such as language, visuospatial ability, and memory, and these deficits worsen when accompanied by hypercholesterolemia⁹. A community-based study on 3,824 individuals aged 65 and older, followed over 3.2 years, revealed that patients on regular antihypertensive medication had a reduced risk of developing Alzheimer's disease¹⁰. This was possibly due to a lower density of neurofibrillary tangles and senile plaques in the hippocampus, a key area affected in Alzheimer's disease.

Dyslipidemia, particularly elevated total cholesterol, also poses a significant risk for dementia. A study involving 9,294 elderly individuals across three French cities showed that hyperlipidemia increased the risk of dementia. Patients taking lipid-lowering medications were found to have a 40% lower risk of dementia¹¹. The accumulation of beta-amyloid plaques, a hallmark of Alzheimer's disease, is accelerated by hypercholesterolemia, contributing to cognitive decline¹². In our analysis, patients with dyslipidemia exhibited significantly higher levels of cognitive impairment compared to those without, with a statistically significant difference ($p < 0.001$).

Type II diabetes is a well-established risk factor for Alzheimer's disease and mixed dementia (a combination of Alzheimer's and vascular dementia), particularly in individuals with the ApoE E4 allele¹³. When diabetes develops in middle age, it significantly increases the risk of Alzheimer's and vascular dementia. Both genetic and environmental factors contribute to this heightened risk. A study by Nooyens ACJ et al., which followed 2,613 individuals aged 40 to 70 over five years, found that those with diabetes experienced a decline in cognitive function that was 2.6 times greater than those without the disease. Among individuals over 60, cognitive decline progressed nearly four times faster in those with diabetes¹⁴.

Patients with multiple vascular risk factors demonstrated more severe cognitive decline compared to those with fewer risk factors. Several studies on Alzheimer's disease have found that vascular comorbidities increase the risk of developing Alzheimer's. Furthermore, the presence of vascular risk factors intensifies the pathological damage seen in Alzheimer's, worsening cognitive symptoms¹⁵. Vascular risk factors for dementia include hypertension, hypercholesterolemia, diabetes, cardiovascular disease, elevated homocysteine levels, and inflammatory markers. In our study, patients with a higher number of risk factors showed an increase in cognitive impairment, although this did not reach statistical significance, likely due to the small sample size.

V. CONCLUSION

Our study focused on patients aged over 60 years, predominantly those engaged in intellectual activities. We found that 48% of participants experienced cognitive impairment, with mild impairment being the most common at 41.1% based on the MMSE scores. Additionally, cognitive decline significantly increased with age ($p < 0.05$). Patients with vascular risk factors, including hypertension, diabetes mellitus, and dyslipidemia, showed higher levels of cognitive impairment ($p < 0.05$). Furthermore, cognitive decline tended to increase with the number of risk factors present,

although this trend did not reach statistical significance ($p>0.05$).

REFERENCES

1. American Psychiatric Association (2013) *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. American Psychiatric Publishing.
2. Creavin ST, Wisniewski S, Noel-Storr AH et al (2016) *Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations*. Cochrane Database Syst Rev 2016(1):CD011145. doi:10.1002/14651858.CD011145.pub2.
3. Doan Vuong Diem Khanh, Vo Van Thang, Ho Dung et al (2015) *Prevalence of dementia among the elderly and healthcare needs in an urban community of central Vietnam*. Vietnam Journal of Public Health 3(1): 16-23.
4. Bich NN, Dung NTT, Vu T et al (2019) *Dementia and associated factors among the elderly in Vietnam: A cross-sectional study*. International Journal of Mental Health Systems. 13: 14-26. doi:10.1186/s13033-019-0314-76.
5. Prince M, Wimo A, Guerchet M et al (2015) *World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends*. Alzheimer's Disease International (ADI).
6. Lê Văn Thính (2007) *Sa sút trí tuệ nguyên nhân mạch máu: vai trò của tai biến nhồi máu não. Tai biến mạch máu não hướng dẫn chẩn đoán và xử trí*. Nhà xuất bản Y học, Hà Nội, tr. 353-370.
7. Brookmeyer R, Evans DA, Hebert L et al (2011) *National dementia prevalence of Alzheimer's disease in the United States*. Alzheimer's & Dementia 7: 61-73.
8. Mathillas J, Lovhbm H, Gustafson Y (2011) *Increasing dementia prevalence among the very old*. Age and Ageing 40: 243-249.
9. Galdstein FC, Ashley AV, Endeshaw YW et al (2008) *Effects of hypertension and hypercholesterolemia on cognitive function in patients with Alzheimer's disease*. Alzheimer's Disease and Associated Disorders 22: 336-342.
10. Bermejo-Pareja F, Benito-León J, Louis ED et al (2010) *Risk of incident dementia in drug-untreated arterial hypertension: A population-based study*. Journal of Alzheimer's Disease 22: 949-958.
11. Dufouil C, Richard F, Fievet N et al (2005) *APOE genotype, cholesterol levels, lipid-lowering treatment, and dementia: The Three-City Study*. Neurology 64: 1531-1538.
12. Morley JE, Banks WA (2010) *Lipids and cognition*. Journal of Alzheimer's Disease 20: 734-747.
13. Akomolafe A, Beiser A, Meigs JB et al (2006) *Diabetes mellitus and risk of developing Alzheimer's disease: Results from the Framingham Study*. Archives of Neurology 63: 1551-1555.
14. Nooyens ACJ, Baan CA, Spijkerman AMW et al (2010) *Type 2 diabetes and cognitive decline in middle-aged individuals*. Diabetes Care 33: 1964-1969.
15. Meikel MM, Rosenberg PB, Tschanz J et al (2007) *Vascular factors predict rate of progression in Alzheimer's disease*. Neurology 60: 1850-1858.